
|Articles|September 26, 2016
PAREXEL to Acquire ExecuPharm
Acquisition of function service provider ExecuPharm addresses what PAREXEL sees as a growing trend among biopharm companies to use combinations of outsourcing models.
Advertisement
PAREXEL has entered into a definitive agreement to acquire ExecuPharm, a global functional service provider (FSP) serving the biopharmaceutical industry. The acquisition is intended to address sponsors’ growing usage of combining different outsourcing models. The FSP offers the ability to outsource specific trial functions tactically, on a particular trial, or strategically to constitute or supplement an entire department.
Read the full
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Agentic AI and the Administrative Backbone of Clinical Trials: Why the Operating Model Has to Change First
2
AI Moves Patient Recruitment from Trial Bottleneck to Competitive Edge: A 2026 Perspective
3
Introducing The Human Side of Clinical Trials
4
Why Quantifying the Financial Value of RBQM Has Been So Hard—and What This Study Did Differently
5




